CBA 29th Annual Conference

Date: June 09, 2024

Location: Marriott Washingtonian Center (9751 Washingtonian Blvd, Gaithersburg, MD 20878)

The Chinese Biopharmaceutical Association (CBA) 29th Annual Conference convened on June 09, 2024, Sunday at Marriott Washingtonian Center (9751 Washingtonian Blvd, Gaithersburg, MD 20878). The conference was held both in-person and online simultaneously.

The theme of the conference was “Pioneering Biopharma Innovations: Scientific Breakthroughs, Global Development & Regulatory Harmonization, and Entrepreneurship“, including six forums:

Scientific & Regulatory Innovations in Drug Development
Accelerate Precision Drug Development through Innovation and Global Partnership
Clinical Strategies in the New Era of Drug Development
CMC Strategy in New Drug Development
Harnessing Artificial Intelligence & Machine Learning to Improve Drug Development Efficiency
Startup Competition

Many outstanding speakers from academia, government, and industry were confirmed on-site presentations. They are Dr. Mitchell Ho, Deputy Chief and Director, NIH, NCI; Dr. ShaAvhrée Buckman-Garner, Director of the Office of Translational Science, FDA, CDER; Dr. Marwan Fathallah, President and CEO, DIA Global; Dr. Raju Kucherlapati, Paul C. Cabot Professor of Genetics and Professor of Medicine, Harvard Medical School; Dr. Puja Sapra, Senior Vice President, Biologics Engineering & Targeted Delivery, Oncology R&D, AstraZeneca; Dr. Sheng Yao, CEO of TopAlliance, SVP and Board member, Junshi Bioscience; Dr. Lei Zheng, Professor of Oncology/Surgery, Director, Pancreatic Cancer Precision Medicine Center of Excellence Program, Johns Hopkins University School of Medicine, etc.

The speakers included clinical and research professors, as well as founders and executives of biotech companies, and FDA drug review experts. The conference covered cutting-edge achievements in basic research, the latest drug developments of different fields in pharmaceutical industry, in-depth discussions on government regulatory policies and approval, and conversations about the challenges and opportunities of biotech investment.